Exagen Inc. to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences:

BTIG at Snowbird: MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Management will participate in one-on-one investor meetings on Tuesday, February 11ᵗʰ, 2025, at the Cliff Lodge located in Snowbird, UT.

TD Cowen’s 45ᵗʰ Annual Health Care Conference

John Aballi, President and CEO and Jeff Black, CFO, will participate in a fireside chat at 1:10 p.m. EST on Wednesday, March 5ᵗʰ, 2025, at the Marriott Copley Place in Boston, MA. Management will also participate in one-on-one investor meetings.

5ᵗʰ Annual KeyBanc Capital Markets Healthcare Forum

Management will participate virtually in a fireside chat at a time to be determined and one-on-one investor meetings on Tuesday, March 18ᵗʰ, 2025.

Please check the Events section of the Investors page on Exagen.com for more information and links to the fireside chats.

About Exagen

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE^® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.

For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).

Exagen Inc.
Ryan Douglas
[email protected]
760.560.1525

You May Also Be Interested In

• Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
• Correct Pack to Showcase Coding and Marking Solutions at Propack Asia 2026
• ACTG Launches HIV Cure Study Evaluating Novel Approach Targeting the HIV Reservoir